Ionis Pharmaceuticals Stock Performance
| IONS Stock | USD 81.36 0.76 0.94% |
On a scale of 0 to 100, Ionis Pharmaceuticals holds a performance score of 8. The company retains a Market Volatility (i.e., Beta) of 0.9, which attests to possible diversification benefits within a given portfolio. Ionis Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Ionis Pharmaceuticals is expected to follow. Please check Ionis Pharmaceuticals' maximum drawdown, as well as the relationship between the skewness and day typical price , to make a quick decision on whether Ionis Pharmaceuticals' current trending patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Ionis Pharmaceuticals are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively inconsistent basic indicators, Ionis Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in March 2026. ...more
Actual Historical Performance (%)
One Day Return 0.94 | Five Day Return (3.37) | Year To Date Return 2.12 | Ten Year Return 110.02 | All Time Return 713.6 |
1 | Disposition of 16777 shares by Shannon Devers of Ionis Pharmaceuticals at 53.77 subject to Rule 16b-3 | 11/25/2025 |
2 | Is It Too Late to Consider Ionis After Its 126 percent Surge in 2025 | 12/17/2025 |
3 | Insider Trading | 12/19/2025 |
4 | Disposition of 30203 shares by Oneil Patrick R. of Ionis Pharmaceuticals at 56.78 subject to Rule 16b-3 | 12/30/2025 |
5 | Acquisition by Elizabeth Hougen of 25770 shares of Ionis Pharmaceuticals at 79.67 subject to Rule 16b-3 | 01/02/2026 |
6 | GSK, Ionis claim study success for RNA-based hepatitis B drug | 01/07/2026 |
7 | Disposition of 2850 shares by Baroldi Joseph of Ionis Pharmaceuticals subject to Rule 16b-3 | 01/15/2026 |
8 | Disposition of 1149 shares by Baroldi Joseph of Ionis Pharmaceuticals at 75.78 subject to Rule 16b-3 | 01/16/2026 |
9 | Acquisition by Shannon Devers of 17377 shares of Ionis Pharmaceuticals subject to Rule 16b-3 | 01/20/2026 |
10 | Assessing Ionis Pharmaceuticals Valuation After TRYNGOLZA Sales Beat And Pipeline Progress | 01/21/2026 |
11 | Acquisition by Birchler Brian of 25800 shares of Ionis Pharmaceuticals subject to Rule 16b-3 | 01/23/2026 |
12 | Acquisition by Baroldi Joseph of 10278 shares of Ionis Pharmaceuticals subject to Rule 16b-3 | 01/29/2026 |
13 | Great Lakes Advisors LLC Decreases Holdings in Ionis Pharmaceuticals, Inc. IONS | 01/30/2026 |
14 | Disposition of 48626 shares by Bennett C Frank of Ionis Pharmaceuticals at 60.89 subject to Rule 16b-3 | 02/02/2026 |
15 | Insider Selling Ionis Pharmaceuticals CEO Sells 62,970 Shares of Stock | 02/03/2026 |
16 | Dawnzera Approval And Pipeline Wins Could Be A Game Changer For Ionis Pharmaceuticals | 02/05/2026 |
17 | Disposition of 29430 shares by Brett Monia of Ionis Pharmaceuticals at 85.7907 subject to Rule 16b-3 | 02/06/2026 |
18 | Disposition of 5000 shares by Parshall B Lynne of Ionis Pharmaceuticals at 82.7177 subject to Rule 16b-3 | 02/11/2026 |
19 | Disposition of 6207 shares by Eric Swayze of Ionis Pharmaceuticals at 82.0691 subject to Rule 16b-3 | 02/13/2026 |
20 | Ionis updates time for fourth quarter and full year 2025 financial results webcast | 02/17/2026 |
| Begin Period Cash Flow | 399.3 M | |
| Total Cashflows From Investing Activities | -134 M |
Ionis Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 7,312 in Ionis Pharmaceuticals on November 20, 2025 and sell it today you would earn a total of 824.00 from holding Ionis Pharmaceuticals or generate 11.27% return on investment over 90 days. Ionis Pharmaceuticals is currently generating 0.1972% in daily expected returns and assumes 1.8137% risk (volatility on return distribution) over the 90 days horizon. In different words, 16% of stocks are less volatile than Ionis, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ionis Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Ionis Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 81.36 | 90 days | 81.36 | about 33.34 |
Based on a normal probability distribution, the odds of Ionis Pharmaceuticals to move above the current price in 90 days from now is about 33.34 (This Ionis Pharmaceuticals probability density function shows the probability of Ionis Stock to fall within a particular range of prices over 90 days) .
Ionis Pharmaceuticals Price Density |
| Price |
Predictive Modules for Ionis Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Ionis Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Ionis Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Ionis Pharmaceuticals is not an exception. The market had few large corrections towards the Ionis Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Ionis Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Ionis Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.14 | |
β | Beta against Dow Jones | 0.90 | |
σ | Overall volatility | 3.46 | |
Ir | Information ratio | 0.08 |
Ionis Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Ionis Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Ionis Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 705.14 M. Net Loss for the year was (453.9 M) with profit before overhead, payroll, taxes, and interest of 73.71 M. | |
| Ionis Pharmaceuticals currently holds about 2.04 B in cash with (500.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.36. | |
| Ionis Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Ionis updates time for fourth quarter and full year 2025 financial results webcast |
Ionis Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Ionis Stock often depends not only on the future outlook of the current and potential Ionis Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Ionis Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 149.5 M | |
| Cash And Short Term Investments | 2.3 B |
Ionis Pharmaceuticals Fundamentals Growth
Ionis Stock prices reflect investors' perceptions of the future prospects and financial health of Ionis Pharmaceuticals, and Ionis Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ionis Stock performance.
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.0568 | ||||
| Profit Margin | (0.27) % | ||||
| Operating Margin | (1.02) % | ||||
| Current Valuation | 12.3 B | ||||
| Shares Outstanding | 161.97 M | ||||
| Price To Earning | 101.16 X | ||||
| Price To Book | 21.13 X | ||||
| Price To Sales | 13.50 X | ||||
| Revenue | 705.14 M | ||||
| Gross Profit | 73.71 M | ||||
| EBITDA | (353.72 M) | ||||
| Net Income | (453.9 M) | ||||
| Cash And Equivalents | 2.04 B | ||||
| Cash Per Share | 14.36 X | ||||
| Total Debt | 1.42 B | ||||
| Debt To Equity | 2.00 % | ||||
| Current Ratio | 8.18 X | ||||
| Book Value Per Share | 3.83 X | ||||
| Cash Flow From Operations | (500.95 M) | ||||
| Earnings Per Share | (1.61) X | ||||
| Market Capitalization | 13.06 B | ||||
| Total Asset | 3 B | ||||
| Retained Earnings | (2.25 B) | ||||
| Working Capital | 2.31 B | ||||
| Current Asset | 837 M | ||||
| Current Liabilities | 148.88 M | ||||
About Ionis Pharmaceuticals Performance
Assessing Ionis Pharmaceuticals' fundamental ratios provides investors with valuable insights into Ionis Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Ionis Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 366.49 | 440.91 | |
| Return On Tangible Assets | (0.15) | (0.14) | |
| Return On Capital Employed | (0.16) | (0.17) | |
| Return On Assets | (0.15) | (0.14) | |
| Return On Equity | (0.69) | (0.73) |
Things to note about Ionis Pharmaceuticals performance evaluation
Checking the ongoing alerts about Ionis Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ionis Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 705.14 M. Net Loss for the year was (453.9 M) with profit before overhead, payroll, taxes, and interest of 73.71 M. | |
| Ionis Pharmaceuticals currently holds about 2.04 B in cash with (500.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.36. | |
| Ionis Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Ionis updates time for fourth quarter and full year 2025 financial results webcast |
- Analyzing Ionis Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ionis Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Ionis Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ionis Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ionis Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ionis Pharmaceuticals' stock. These opinions can provide insight into Ionis Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.